title: Biotechnological challenges of phage therapy.
abstract: The challenges for successful launching of a profitable phage therapeutic product include intellectual property rights, safety issues, reproducibility, stability and robustness of the product. A successful and marketable product would be a highly purified bacteriophage preparation containing one or several fully characterized phages, accompanied by optimized methods of administration and backed up by properly controlled efficacy and safety studies.
authors.affiliation: Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland. mikael.skurnik@helsinki.fi
authors.forename: Mikael
authors.initials: M
authors.lastname: Skurnik
authors.forename: Maria
authors.initials: M
authors.lastname: Pajunen
authors.forename: Saija
authors.initials: S
authors.lastname: Kiljunen
mesh_terms: D001435:Bacteriophages / Q000235:genetics / Q000378:metabolism* / Q000472:pathogenicity; D001709:Biotechnology / Q000191:economics / Q000379:methods* / Q000592:standards* / Q000639:trends; D016679:Genome, Viral / Q000235:genetics; D017422:Sequence Analysis, DNA; D014118:Toxins, Biological; D037521:Virulence Factors
chemical_list: D014118:Toxins, Biological; D037521:Virulence Factors